Limitations, agreements, and source contact

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer · Source last updated 2021-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

Jennifer.Louie2@pennmedicine.upenn.edu

organization

University of Pennsylvania

phone

267-414-6179

title

Jennifer Louie, Program Manager

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice